Kornimate/medical-research-clean huggingface dataset:
effect of intrauterine administration of autologous pbmc modulated with ifnt on ivf outcome

Conditions: Infertility, Female; IVF

Summary: the goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the ivf outcome (implantation, pregnancy and live birth rates). to achieve this, blood will be obtained from eligible participants. target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer. researchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.

female patients with no known uterine pathologies scheduled to undergo embryo transfer will be identified through patient records and invited to participate in the study. five days after luteinizing hormone (lh) surge, peripheral blood mononuclear cells (pbmc) will be isolated from these patients' peripheral blood by density gradient centrifugation and suspended in culture medium. the obtained pbmc will be incubated with 500 iu/ml ifnt at 37˚c for 24 hours. this cell suspension will be carefully introduced in the uterine cavity by catheter on day 6 post lh surge. embryo transfer will be performed the following day. a suitable age-matched control group will be recruited that will undergo embryo transfer but will not be administered immunomodulated pbmc prior to the transfer. reproductive outcomes in terms of rate of implantation, rate of clinical pregnancy and live birth rates will be recorded and compared between the two groups. data analysis will be performed by investigators blind to the patient group.

Eligibility criteria:
inclusion criteria: * participating in assisted reproduction treatment * having primary infertility * having regular menstrual cycles * scheduled to undergo embryo transfer of euploid embryos only exclusion criteria: * uterine pathologies * endometrial bacterial infections * active endometrial inflammation * polycystic ovary syndrome * presence of auto antibodies such as anti-tpo (thyroid peroxidase), anti-tg (thyroglobulin), aca (anticentromere antibodies), apa (antiphospholipid antibodies), ana (antinuclear antibodies), and anti-dsdna * presence of mutations involving the coagulation system such as deficiency of factor xii, pro c, pro s * oncological condition * positive hiv (human immunodeficiency virus), hcv (hepatitis c virus) or hbv (hepatitis b virus) tests

Keywords: intrauterine pbmc interferon tau implantation clinical pregnancy live birth rate
video-assisted intervention in improving recovery in patients with cancer undergoing lung surgery and caregivers

Conditions: Malignant Lung Neoplasm

Summary: this pilot clinical trial studies a video-assisted intervention in improving recovery of patients undergoing surgery to remove lung cancer or cancer that has spread to the lung and their caregivers. the intervention uses educational videos to prepare patients and families for surgery and teach them how to manage the symptoms after surgery. teaching patients and their families what to expect before and after surgery may help improve patient and caregiver quality of life, help patients recover better from surgery, and support families in their role as caregivers after surgery.

primary objectives: i. to pilot test a video-assisted intervention designed to enhance post-operative recovery by preparing patients and informal caregivers for lung surgery. secondary objectives: i. to describe preliminary effect of the video-assisted intervention on patient-reported outcomes (pros), informal caregiver-reported outcomes, and clinical/system outcomes. outline: patients and their caregivers are assigned to 1 of 2 arms. arm i: patients and caregivers receive standard care during routine clinic visits. arm ii: patients view parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. patients then receive an educational handbook and discuss the video with a nurse. after surgery and before hospital discharge, patients view part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home. after completion of study, patients and caregivers are followed up at approximately 2-4 weeks and 2 months.

Eligibility criteria:
inclusion criteria: * patients: scheduled to undergo surgery with lung resection for treatment of primary or secondary neoplasms of the lung * patients: able to read and understand english * informal caregivers: the primary informal caregiver as identified by patients participating in the study; this refers to either a family member or friend who will be providing the majority of care following surgery * informal caregivers: able to read and understand english * this protocol is eligible for waiver of informed consent documentation; all subjects must have the ability to understand and the willingness to provide verbal informed consent exclusion criteria: * subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
effectiveness of platelet-rich plasma for treatment of trigger finger

Conditions: Tendon Entrapment

Summary: study purpose is to evaluate the effectiveness of platelet-rich plasma (prp) injection in the treatment of trigger finger. we compare prp to a corticosteroid (methylprednisolone) injection in a prospective randomized triple-blind placebo-controlled study. patients with clinically confirmed trigger finger are randomized (1:1:1 computer generated sequence with random block size) to three parallel groups and will receive an injection of either prp, corticosteroid or placebo (0.9% saline) around the affected tendon sheath in a double-blind setting. baseline data is collected and is followed by a phone call at 1 month, and follow-up visits at 3, 6, 12 and 24 months after the intervention. unveiling of the allocation is at 6 months post-intervention. the primary outcome measures are: * symptom resolution * patient-rated wrist evaluation secondary outcomes: * quick-disabilities of the arm, shoulder and hand * pain visual analogue score * global improvement (7-step likert-scale) * grip strength * finger range of motion


Eligibility criteria:
inclusion criteria: * age 18 - 75 * symptom duration \> 3 months exclusion criteria: * diabetes * rheumatoid arthritis or other condition requiring continuous oral corticosteroids * previous history of surgery or injection to the affected ray * alcohol or drug abuse * mental instability

Keywords: platelet-rich plasma trigger finger
hydroxychloroquine, oseltamivir and azithromycin for the treatment of covid-19 infection: an rct

Conditions: COVID 19

Summary: to evaluate the effectiveness of hydroxychloroquine sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).

a scientific taskforce notified by the ministry of science and technology of the government of pakistan will oversee a comprehensive cohort study. within this cohort, a multicenter, adaptive, randomized controlled trial will evaluate, among eligible sars-cov-2 (covid-19) infected patients receiving standard supportive care who consent to randomization following a new diagnosis in pakistan, if hydroxychloroquine sulfate alone (control intervention) vs a series of alternatives (comparator interventions) including oseltamivir and azithromycin alone and in combination with hydroxychloroquine sulfate is effective in clearing the coronavirus and improving the clinical course of the disease. those not consenting to randomization will be followed up for outcomes of sars-cov-2 infection with supportive care only. findings of this study are expected to inform clinical care and public health protocols and policies for management of sars-cov-2.

Eligibility criteria:
inclusion criteria: 1. confirmed sars-cov-2 (covid-19) infection by a positive test result 2. either gender 3. symptomatic for example fever, dry cough, difficulty to breathe exclusion criteria: 1. confirmed absence of sars-cov-2 (covid-19) infection by a negative test result 2. have chronic conditions such as heart disease, liver and kidney failure 3. pregnant or currently lactating 4. immunocompromise and/or systemic disease(s) 5. on other antiviral drugs 6. history of allergy to any of the drugs to be administered in this study
impact of mk-0518 (raltegravir) intensification on hiv-1 viral latency in patients with previous complete viral suppression

Conditions: HIV Infections

Summary: an intensification with the hiv-1 integrase inhibitor raltegravir (ral) of a stable haart regimen with persistent hiv-1 viral suppression could increase the slope of decay of the hiv-1 latent reservoir.

while highly active antiretroviral therapy (haart) reduces plasma hiv-1 levels to below the limits of detection with standard assays, replication-competent virus persist in a stable, latent reservoir in resting cd4+ t cells. so, there is a rapid resumption in plasma viremia when therapy is interrupted. in addition to cellular reservoir, other pharmacologically privileged areas such as the central nervous system and the genital tract might act as additional sources of residual virus in patients with undetectable levels of plasma hiv-1 rna. there is great current interest in strategies for depleting and eliminating this reservoir. the antiviral potency of current regimens emerges as an important determinant of complete viral control. in certain patients, the latent reservoir decay can be hastened with treatment intensification. an intensification with the hiv-1 integrase inhibitor raltegravir (ral) of a stable haart regimen with persistent hiv-1 viral suppression could increase the slope of decay of the hiv-1 latent reservoir. this could provide further insight into this area, decrease the size of latent reservoir, and translate into clinical benefits for patients being simplified to maintenance monotherapy with ral or in the hiv-1 rebound kinetics and slope after a programmed treatment interruption.

Eligibility criteria:
inclusion criteria: 1. hiv-1 infected adults (+18 years old). 2. complete virological suppression (\<50 copies/ml) for += 12 months, including at least 3 times during the last year. 3. patients on haart regimen including a pi or an nnrti and at least two nucleotide inhibitors. 4. voluntary written informed consent. exclusion criteria: 1. pregnancy, or fertile women willing to be pregnant. 2. active substance abuse or major psychiatric disease. 3. presence of drug-related mutations or any polymorphism or mutation associated to mk-0518 resistance prior to first haart (only if genotype is available).

Keywords: raltegravir mk-0518 treatment intensification hiv-1 latency hiv eradication treatment experienced
validity and reliability of the modified four square step test in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: balance disorder is common in people with ms. as the disease worsens, it is associated with impaired balance, difficulty walking, decreased mobility, and an increased risk of falling. given the prevalence and clinical significance of balance dysfunction in individuals with ms, the assessment of balance has become an important focus in ms clinical practice and research. the four square step test is a standard clinical measure used to assess dynamic standing balance. it is a timed test in which the individual is instructed to step rapidly forward, backward, and to the right and left over a low obstacle (a cane). the test assesses the ability to quickly change direction of movement and is a timed test involving the use of assistive devices. in the modified four-square stepping test, the floor is divided into four equal squares with tape instead of a cane. performing the test with tape, instead of patients at risk of being stuck with a cane, will ensure its applicability to a wider patient population. the aim of the study is to examine the validity and reliability of the modified four-frame stepping test in ms patients.

multiple sclerosis (ms) is a progressive disease of the central nervous system characterized by demyelination and destruction of motor and sensory axons. as the disease worsens, it is associated with impaired balance, difficulty walking, decreased mobility, and an increased risk of falling. the prevalence of balance dysfunction in individuals with ms and given its clinical relevance, the assessment of balance has become an important focus in ms clinical practice and research.the four square step test is a standard clinical measure used to assess dynamic standing balance.the individual rapidly forwards over a low obstacle (a cane), is a timed test in which instructed to step backward and to the right and left.the four-frame stepping test was developed to document deficiencies in stance balance, predict falls, assess self-perceived limitations in walking, and compare changes in standing balance following exercise training. compared to other standardized tests, scoring is not dependent on the subjectivity of the examiner, can be administered by a person with minimal training, and requires minimal time, space, and equipment. in the modified four-square stepping test, the floor is divided into four equal squares with tape instead of a cane. performing the test with tape, instead of patients at risk of being stuck with a cane, will ensure its applicability to a wider patient population.

Eligibility criteria:
inclusion criteria: * having an edss score of 4 and below, * being between the ages of 18-65 * willingness to participate in the study exclusion criteria: * being pregnant or within the first 3 months after giving birth, * receiving corticosteroid therapy in the last 1 month, * using drugs that will affect walking in the last 1 month

Keywords: fall modified four square step test multiple sclerosis balance
the effects of acute melatonin supplementation on cardiovascular responses to sympathetic activation

Conditions: Healthy

Summary: the purpose of this experiment is to determine if acute melatonin supplementation alters central and peripheral cardiovascular responses to a cold pressor test at rest and during dynamic exercise.

after irb approval, experiments will take place in the human circulation research laboratory in the department of health and exercise on the university of oklahoma norman campus. all subjects will complete a total of 3 visits. the first is a screening visit to provide informed consent and to ensure the potential participant meets all inclusion criteria and no exclusion criteria. once consented and enrolled, participants will be familiarized with experimental protocols. on separate days (visits 2 and 3), participants will complete placebo (pla) and melatonin (mel) in a randomly ordered, single-blind, counter-balanced design. pla or mel treatment will precede testing by 30min to maximize absorption into the circulation (bartoli, 2013). all experiments (pla/mel) will begin with the subject lying supine for 5 min of quiet rest where baseline measurements are taken, followed by activation of the lower body negative pressure (lbnp) device causing suction at -20 mmhg. following lbnp participants will be given 10 minutes of rest to recover all variables to pre-lbnp values. after which participants will be given a hand grip dynamometer to complete 7 minutes of exercise at an intensity of 20% mvc at a 1s contraction to 2s relaxation cycle paced by a metronome. during the final 2 minutes of the 7 minutes of exercise the lbnp device will be activated again to -20mmhg such that the participant will be completing lbnp during rhythmic grip exercise. after the completion of exercise, the subject will remain supine for 10min. then the a total labile signal (tls) procedure will be conducted. where the experimental limb is occluded using a blood pressure cuff for 5min. the cuff is then rapidly deflated. the lowest oxyhemoglobin measured during the occlusion is recorded. after the tls procedure, the subject will be de-instrumented and will leave the laboratory.

Eligibility criteria:
inclusion criteria: * healthy men and women * women must be premenopausal with a regular menstrual cycle (26-30 days) exclusion criteria: * history of autonomic dysfunction * cardiovascular diseases * diabetes * tobacco/nicotine use * systolic pressure \>= 130 mmhg * diastolic pressure \>= 85 mmhg * regular melatonin use \>= 1 use/week * allergy to melatonin * cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins) * sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone) * pregnancy
evaluating the efficiency of breathing exercises performed by post-covid telemedicine: randomized controlled study

Conditions: Covid19

Summary: as an important non-drug intervention in the treatment of respiratory tract diseases, respiratory rehabilitation training is increasingly accepted in clinical practice. the purpose of pulmonary rehabilitation is not only to improve the physical and mental conditions of the patient, but also to help the patient return to the family and society more quickly. in light of the widely documented lung injuries associated with covid-19, concerns are raised regarding the assessment of lung injury in discharged patients. as an important non-drug intervention in the treatment of respiratory diseases, respiratory rehabilitation training is increasingly being accepted in clinical practice the purpose of pulmonary rehabilitation is not only to improve the physical and mental conditions of the patient, but also to help the patient return to the family and society more quickly. the aim of the study; it is aimed to evaluate the efficiency of breathing exercise in individuals with covid-19.


Eligibility criteria:
inclusion criteria: * 18 years of age or older and who received / will receive treatment with the diagnosis of covid 19 and completed 2 months after the diagnosis of covid 19 * patients who applied to the pulmonary diseases outpatient clinic with complaints of dyspnea * fev1 / fvc \ 50% and / or patients with respiratory distress in daily living activities exclusion criteria: * fev 1 \<50%, fef 25-75 \<50% detected oxygen saturation \<85% at rest, * moderately severe heart failure, * has a disease that restricts its mobilization, * psychiatric illness, * advanced stage liver, advanced stage renal failure, * myocardial infarction within 4 months * having a history of unstable angina * active infectious disease
effectiveness of atropine and glycopyrrolate to reduce hyper salivation with ketamine sedation

Conditions: Sialorrhea

Summary: the purpose of this study is to determine if the antisialagogues (anti-salivary agents), atropine and glycopyrrolate, are effective in reducing hypersalivation when sedating patients with ketamine for procedural sedation in the emergency department or abscess clinic. the investigators will measure salivary flow rate by collecting oral secretions by oral suctioning over a 30 minute time period starting with the administration of ketamine. the investigators hypothesize that patients who receive either atropine or glycopyrrolate will have fewer oral secretions than patients who receive placebo.

ketamine is a common sedation agent used in the pediatric emergency department for a variety of procedures, used in clinical practice since 1970. one potential side effect of ketamine is hypersalivation, potentially leading to laryngospasms. to prevent hypersalivation (and reduce the potential for laryngospasms), an anti-salivary agent, such as atropine, is commonly given in combination with ketamine. recently, however, the necessity of this practice has been brought into question. the consideration of using a different drug, glycopyrrolate, has been debated. the purpose of this study is to compare the effectiveness of each medication in addition to the placebo control. patients enrolled into this study must present to the emergency department or abscess clinic with the need to receive ketamine as part of a sedation procedure (as determined by the treating physician). this study will randomize enrolled patients to receive double-blinded atropine, glycopyrrolate or placebo given 30 minutes prior to ketamine. after ketamine is administered, a trained medical person will suction the patient's mouth every 5 minutes for a total of 30 minutes, collecting all oral secretions. total saliva production will be measured and salivary flow rates will be calculated and compared between each assigned group. adverse events and complications will be monitored throughout the patient's stay in the emergency department or abscess clinic.

Eligibility criteria:
inclusion criteria: * children age 6 months to 18 years (inclusive) presenting to children's medical center emergency department or abscess clinic. * children whom the attending physician feels need procedural sedation with the intravenous medication, ketamine. exclusion criteria: * children who are asa class iii or greater. * children with an allergy or contraindication to ketamine, atropine or glycopyrrolate. * inability to tolerate oral suctioning. * any condition or situation whereby the patient would be unable to have his/her head turned to one side. * patient history of vomiting or diarrhea in the last 24 hours * patients who have taken an anti-sialogogue within the previous 24 hours. * patients that need to receive midazolam or other benzodiazepines.

Keywords: hypersalivation conscious sedation procedural sedation ketamine atropine glycopyrrolate